Compare · ABVX vs NVO
ABVX vs NVO
Side-by-side comparison of Abivax SA (ABVX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABVX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $167.46B, about 26.2x ABVX ($6.39B).
- Over the past year, ABVX is down 40.3% and NVO is down 20.6% - NVO leads by 19.7 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 3 for ABVX).
- NVO has more recent analyst coverage (25 ratings vs 17 for ABVX).
- Company
- Abivax SA
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $6.39B
- $167.46B
- 1M return
- -18.77%
- -4.16%
- 1Y return
- -40.28%
- -20.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 3
- 9
- Recent ratings
- 17
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ABVX
- Abivax Statement on Short Seller Report
- Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA
- Abivax to Participate in Upcoming Fall Investor Conferences
- Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
- SEC Form F-6EF filed by Abivax SA
- SEC Form 6-K filed by Abivax SA
- Abivax Presents Business Updates and First Half 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA
- Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
- Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S